<p><strong>Liquidia Corporation</strong>（納斯達克代碼：LQDA）在經歷了一段動盪時期後，最近一個月的表現非常出色，股價上漲了 30%。上個月的漲幅為過去一年內 213% 的大幅增長畫上了句號。</p>
<p>在如此大幅的價格跳升之後，Liquidia 的市銷率（或稱&#34;P/S&#34;）為 43.2 倍，這使得與美國製藥行業的其他公司相比，它看起來像是一個強烈的賣出信號，而在該行業中，大約一半的公司市銷率低於 4 倍，甚至市銷率低於 1.3 倍的情況也相當普遍。不過，僅僅根據市銷率的表面值來判斷並不明智，因為可能有解釋其如此高的原因。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對 Liquidia 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896"/></p>
<p>納斯達克 CM:LQDA 市銷率與行業對比 2025 年 12 月 6 日</p>
<h3>Liquidia 最近的表現如何？</h3>
<p>最近一段時間對 Liquidia 來説是有利的，因為其收入增長速度超過了大多數其他公司。似乎許多人預計強勁的收入表現將持續下去，這提高了市銷率。然而，如果情況並非如此，投資者可能會因支付過高的股價而受到影響。</p>
<p>如果您想了解分析師對未來的預測，您應該查看我們關於 Liquidia 的 <strong>免費</strong> 報告。</p>
<h2>Liquidia 的收入增長趨勢如何？</h2>
<p>您真正能夠安心看到 Liquidia 如此高的市銷率的唯一時機是當公司的增長顯著超越行業時。</p>
<p>回顧過去，我們看到公司在過去 12 個月的收入經歷了快速增長。最近三年期間，收入也經歷了令人難以置信的整體增長，這得益於其出色的短期表現。因此，可以公平地説，最近的收入增長對公司來説是極好的。</p>
<p>展望未來，預計未來三年將每年產生 118% 的增長，這是由八位關注該公司的分析師估算的。與行業每年僅預測增長 30% 相比，該公司有望實現更強的收入結果。</p>
<p>鑑於此，Liquidia 的市銷率高於大多數其他公司是可以理解的。似乎大多數投資者都在期待這種強勁的未來增長，並願意為該股票支付更高的價格。</p>
<h2>我們可以從 Liquidia 的市銷率中學到什麼？</h2>
<p>強勁的股價飆升導致 Liquidia 的市銷率也隨之飆升。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
<p>我們已經確定 Liquidia 維持其高市銷率的原因在於其預測的收入增長高於製藥行業的其他公司，正如預期的那樣。看來，股東對公司的未來收入充滿信心，這支撐了市銷率。除非分析師們真的大錯特錯，否則這些強勁的收入預測應該會保持股價的穩定。</p>
<p>在您採取下一步之前，您應該瞭解我們發現的 <strong>Liquidia 的一個警示信號</strong>。</p>
<p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他強勁盈利增長和低市盈率公司的集合。</p>

LQDA

<p>Liquidia Corporation（納斯達克代碼：LQDA）的股價最近上漲了 30%，使其在過去一年中累計增長了 213%。儘管其市銷率高達 43.2 倍，但由於強勁的收入增長預測，投資者仍然持樂觀態度，預計未來三年年增長率將達到 118%，而行業平均為 30%。高市銷率反映了投資者的情緒和未來預期，但由於潛在風險，仍需保持謹慎</p>

<p><strong>Liquidia Corporation</strong> (NASDAQ:LQDA) shares have had a really impressive month, gaining 30% after a shaky period beforehand. The last month tops off a massive increase of 213% in the last year.</p>
<div class="lb-trans"><p><strong>Liquidia Corporation</strong>（納斯達克代碼：LQDA）在經歷了一段動盪時期後，最近一個月的表現非常出色，股價上漲了 30%。上個月的漲幅為過去一年內 213% 的大幅增長畫上了句號。</p>
</div><p>After such a large jump in price, Liquidia's price-to-sales (or &#34;P/S&#34;) ratio of 43.2x might make it look like a strong sell right now compared to other companies in the Pharmaceuticals industry in the United States, where around half of the companies have P/S ratios below 4x and even P/S below 1.3x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.</p>
<div class="lb-trans"><p>在如此大幅的價格跳升之後，Liquidia 的市銷率（或稱&#34;P/S&#34;）為 43.2 倍，這使得與美國製藥行業的其他公司相比，它看起來像是一個強烈的賣出信號，而在該行業中，大約一半的公司市銷率低於 4 倍，甚至市銷率低於 1.3 倍的情況也相當普遍。不過，僅僅根據市銷率的表面值來判斷並不明智，因為可能有解釋其如此高的原因。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>See our latest analysis for Liquidia</p>
<div class="lb-trans"><p>查看我們對 Liquidia 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896" alt="" original-src="https://images.simplywall.st/asset/chart/22761611-ps-multiple-vs-industry-1-dark-2/1765031919896"/></p>
<p>NasdaqCM:LQDA Price to Sales Ratio vs Industry December 6th 2025</p>
<div class="lb-trans"><p>納斯達克 CM:LQDA 市銷率與行業對比 2025 年 12 月 6 日</p>
</div><h3>What Does Liquidia's Recent Performance Look Like?</h3>
<div class="lb-trans"><h3>Liquidia 最近的表現如何？</h3>
</div><p>Recent times have been advantageous for Liquidia as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>最近一段時間對 Liquidia 來説是有利的，因為其收入增長速度超過了大多數其他公司。似乎許多人預計強勁的收入表現將持續下去，這提高了市銷率。然而，如果情況並非如此，投資者可能會因支付過高的股價而受到影響。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Liquidia.</p>
<div class="lb-trans"><p>如果您想了解分析師對未來的預測，您應該查看我們關於 Liquidia 的 <strong>免費</strong> 報告。</p>
</div><h2>How Is Liquidia's Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>Liquidia 的收入增長趨勢如何？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as steep as Liquidia's is when the company's growth is on track to outshine the industry decidedly.</p>
<div class="lb-trans"><p>您真正能夠安心看到 Liquidia 如此高的市銷率的唯一時機是當公司的增長顯著超越行業時。</p>
</div><p>Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.</p>
<div class="lb-trans"><p>回顧過去，我們看到公司在過去 12 個月的收入經歷了快速增長。最近三年期間，收入也經歷了令人難以置信的整體增長，這得益於其出色的短期表現。因此，可以公平地説，最近的收入增長對公司來説是極好的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 118% each year as estimated by the eight analysts watching the company. With the industry only predicted to deliver 30% per year, the company is positioned for a stronger revenue result.</p>
<div class="lb-trans"><p>展望未來，預計未來三年將每年產生 118% 的增長，這是由八位關注該公司的分析師估算的。與行業每年僅預測增長 30% 相比，該公司有望實現更強的收入結果。</p>
</div><p>In light of this, it's understandable that Liquidia's P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.</p>
<div class="lb-trans"><p>鑑於此，Liquidia 的市銷率高於大多數其他公司是可以理解的。似乎大多數投資者都在期待這種強勁的未來增長，並願意為該股票支付更高的價格。</p>
</div><h2>What We Can Learn From Liquidia's P/S?</h2>
<div class="lb-trans"><h2>我們可以從 Liquidia 的市銷率中學到什麼？</h2>
</div><p>The strong share price surge has lead to Liquidia's P/S soaring as well. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>強勁的股價飆升導致 Liquidia 的市銷率也隨之飆升。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
</div><p>We've established that Liquidia maintains its high P/S on the strength of its forecasted revenue growth being higher than the the rest of the Pharmaceuticals industry, as expected. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.</p>
<div class="lb-trans"><p>我們已經確定 Liquidia 維持其高市銷率的原因在於其預測的收入增長高於製藥行業的其他公司，正如預期的那樣。看來，股東對公司的未來收入充滿信心，這支撐了市銷率。除非分析師們真的大錯特錯，否則這些強勁的收入預測應該會保持股價的穩定。</p>
</div><p>Before you take the next step, you should know about the <strong>1 warning sign for Liquidia</strong> that we have uncovered.</p>
<div class="lb-trans"><p>在您採取下一步之前，您應該瞭解我們發現的 <strong>Liquidia 的一個警示信號</strong>。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他強勁盈利增長和低市盈率公司的集合。</p>
</div>

Liquidia Corporation（NASDAQ:LQDA）股價上漲 30%，表現得恰到好處